The application of induced pluripotent stem cells for bone regeneration: current progress and prospects.
The application of induced pluripotent stem cells for bone regeneration: current progress and prospects.
复制标题
DOI：
10.1089/ten.teb.2013.0301
复制
发表时间：
2014-08
期刊：
影响因子：
--
通讯作者：
S. Teng;Chaoxu Liu;C. Krettek;M. Jagodzinski
中科院分区：
文献类型：
--
作者：
S. Teng;Chaoxu Liu;C. Krettek;M. Jagodzinski
健康骨组织的丢失和成骨障碍仍然是临床上常见的重要问题。使用间充质干细胞（MSC）的基于细胞的治疗已经在患者中进行了相当长的一段时间，但是这些细胞的固有缺点，例如随着衰老发生的增殖率和成骨分化潜力的降低，极大地限制了它们的进一步应用。此外，胚胎干细胞（ESCs）因其完全的多能分化潜力和优异的骨再生性能，为骨再生医学带来了新的希望。然而，涉及破坏人类胚胎的伦理问题和移植后发生的免疫反应是阻碍ESCs临床应用的两大绊脚石。相反，诱导多能干细胞（iPSC）是使用定义的转录因子从成人体细胞重新编程的ESC样多能细胞，被认为是再生医学更有前途的细胞来源，因为它们不存在伦理或免疫学问题。在这里，我们总结了产生iPSC的主要技术和这些细胞的生物学特性，回顾了基于iPSC的骨再生的当前进展，最后，讨论了与这些细胞相关的剩余挑战，特别是安全性问题及其在骨再生医学中的潜在应用。
Loss of healthy bone tissue and dysosteogenesis are still common and significant problems in clinics. Cell-based therapy using mesenchymal stem cells (MSCs) has been performed in patients for quite some time, but the inherent drawbacks of these cells, such as the reductions in proliferation rate and osteogenic differentiation potential that occur with aging, greatly limit their further application. Moreover, embryonic stem cells (ESCs) have brought new hope to osteoregenerative medicine because of their full pluripotent differentiation potential and excellent performance in bone regeneration. However, the ethical issues involved in destroying human embryos and the immune reactions that occur after transplantation are two major stumbling blocks impeding the clinical application of ESCs. Instead, induced pluripotent stem cells (iPSCs), which are ESC-like pluripotent cells that are reprogrammed from adult somatic cells using defined transcription factors, are considered a more promising source of cells for regenerative medicine because they present no ethical or immunological issues. Here, we summarize the primary technologies for generating iPSCs and the biological properties of these cells, review the current advances in iPSC-based bone regeneration and, finally, discuss the remaining challenges associated with these cells, particularly safety issues and their potential application for osteoregenerative medicine.